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 Preimplantation genetic diagnosis (PGD) is gradually widely used in prevention of gene diseases and chromosomal abnormalities. Much im-
provement has been achieved in biopsy technique and molecular diagnosis. Blastocyst biopsy can increase diagnostic accuracy and reduce al-
lele dropout. It is cost-effective and currently plays an important role. Whole genome amplification permits subsequent individual detection of 
multiple gene loci and screening all 23 pairs of chromosomes. For PGD of chromosomal translocation, fluorescence in-situ hybridization (FISH) 
is traditionally used, but with technical difficulty. Array comparative genomic hybridization (CGH) can detect translocation and 23 pairs of chro-
mosomes that may replace FISH. Single nucleotide polymorphisms array with haplotyping can further distinguish between normal chromo-
somes and balanced translocation. PGD may shorten time to conceive and reduce miscarriage for patients with chromosomal translocation. 
PGD has a potential value for mitochondrial diseases. Preimplantation genetic haplotyping has been applied for unknown mutation sites of 
single gene disease. Preimplantation genetic screening (PGS) using limited FISH probes in the cleavage-stage embryo did not increase live 
birth rates for patients with advanced maternal age, unexplained recurrent abortions, and repeated implantation failure. Polar body and blas-
tocyst biopsy may circumvent the problem of mosaicism. PGS using blastocyst biopsy and array CGH is encouraging and merit further studies. 
Cryopreservation of biopsied blastocysts instead of fresh transfer permits sufficient time for transportation and genetic analysis. Cryopreserva-
tion of embryos may avoid ovarian hyperstimulation syndrome and possible suboptimal endometrium. 
Keywords: Array Comparative Genomic Hybridization; Preimplantation Genetic Diagnosis; Preimplantation Genetic Screening; Single Nucleo-
tide Polymorphisms Array; Vitrification; Whole Genome Amplification; Human
Introduction
Preimplantation genetic diagnosis (PGD) was first successfully per-
formed in humans for prevention of X-linked disease in 1990 [1]. It 
gains a gradually important role in the prevention for Mendelian he-
reditary diseases and unbalanced chromosomal translocation. PGD 
provides an alternative of prenatal diagnosis with selective termina-
tion of pregnancy for couples accompanying a high risk of affected 
offspring. More indications have been applied as aneuploidy screen-
ing, human leukocyte antigen (HLA) typing, adult-onset Mendelian 
diseases, cancer predisposition syndromes and mitochondrial dis-
eases [2,3]. Significant advancement has been attained in biopsy 
technique and molecular diagnosis. Vitrification of embryo after blas-
tocyst biopsy permits sufficient time for shipment of specimen and 
diagnosis in the orderly fashion [4]. In this update, we will review in-
dications, present approaches to retrieve cells for PGD, diagnostic 
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technology, accuracy and possible misdiagnosis in details.
PGD for single gene disease and three different 
biopsy approaches
In principle, all monogenic disorders for which prenatal diagnosis is 
available can be examined by PGD as well. Many diseases have been 
successfully applied including thalassemia, cystic fibrosis, hemophilia, 
spinal muscular atrophy, neurofibromatosis, and congenital deafness, 
etc. [1-7]. There are three potential sources of embryonic genetic ma-
terial for PGD, including polar bodies from oocytes, blastomeres from 
cleavage-stage embryos, and trophectoderm cells from blastocysts 
[8,9]. The polar bodies can be used for the indirect genetic analysis of 
the oocyte. The disadvantage is that it does not permit the analysis of 
the paternal genetic material. Since beginning, cleavage-stage biop-
sy with aspiration of one blastomere is the most common approach 
for PGD. In the recent years, blastocyst biopsy is gradually widely 
used. Both of them allow analysis of maternal and paternal origin. 
PCR-based tests using single cell have 
possibility of ADO
Polymerase chain reaction (PCR) of single cells is vulnerable to con-
tamination and allele dropout (ADO). ADO occurs when one of the 
two alleles fails to be amplified and only the other allele is amplified. 
In autosomal-dominant disorders, ADO of the affected allele might 
lead to the transfer of an affected embryo. For autosomal recessive 
conditions, ADO will not cause serious misdiagnosis [7], but the num-
ber of embryos available for transfer would reduce and this may re-
sult in a decreased pregnancy rate. The data of ADO in direct amplifi-
cation of gene locus ranges from 5% to 33% [10,11]. The ADO rates 
in whole genome amplification (WGA) are from 5% to 31% [12,13], 
which are comparable to those obtained by direct amplification of 
gene locus. The incidence of ADO may depend on the cell number 
analyzed, the genes tested, and the lysis conditions, the PCR condi-
tions, or the method of WGA [14]. To reduce the ADO rate below 10% 
would be imperative [15].
Polymorphic markers are helpful to find ADO 
that prevents misdiagnosis
Polymorphic markers with short tandem repeats (STR) or single nu-
cleotide polymorphisms (SNP) close to the mutated gene have been 
used for linkage analysis to provide an additional confirmation of ge-
notyping and an evidence of ADO [16,17]. STR markers also help to 
detect contamination of exogenous DNA with different STR sizes. 
Sufficient numbers (at least three) of linked markers are recommend-
ed to be tested together with the causative gene [15].
Blastocyst biopsy may increase diagnostic 
accuracy and reduce ADO. It is cost-effective 
and may replace cleavage-stage biopsy
Blastocyst biopsy providing more cells than the cleavage-stage bi-
opsy (5-10 cells vs. 1-2 cells) for genetic analysis may potentially re-
duce the risk of amplification failure and ADO [18]. Kokkali et al. [18] 
prospectively compared genotyping success and implantation rates 
in PGD cycles after biopsy at the blastocyst versus the cleavage stage. 
They found that the genotyping success rate was significantly higher 
in the blastocyst group (94%) than in the cleavage-stage group (75%). 
The implantation and pregnancy rates were not statistically different. 
With the higher genotyping success rates, trophectoderm biopsy may 
result in relatively more embryos available for transfer. Trophecto-
derm biopsy would be relatively cost-effective and less labor-inten-
sive, because only embryos competently developing to the blasto-
cyst stage are biopsied. 
Blastocyst biopsy plus vitrification permits 
sufficient time for diagnosis, and may also 
avoid suboptimal endometrium
Embryo biopsy and fresh embryo transfer are traditionally per-
formed in the PGD cycle. However, prior to embryo transfer, the time 
allowed for shipment of the specimens to the reference laboratory 
and performance of molecular diagnosis is limited, especially after 
blastocyst biopsy. Vitrification of blastocysts has been demonstrated 
to achieve high survival rate and pregnancy rate [19]. The strategy of 
PGD for monogenic diseases using blastocyst biopsy, vitrification, 
WGA accompanied by double confirmatory genotypings, and thawed 
embryo transfer have been successfully performed [4]. In addition, 
cryopreservation of embryos may be beneficial for patients of high 
responder to circumvent risk of ovarian hyperstimulation syndrome 
and possible suboptimal endometrium [20-22]. 
PGD for adult-onset autosomal diseases and 
cancer predisposition syndromes
PGD to exclude transmission of an autosomal dominant adult-onset 
disease would be more acceptable to at-risk families than the preg-
nancy termination after prenatal diagnosis. Huntington disease or 
other neurodegenerative diseases have been successfully applied [23]. 
PGD has also been performed for familial cancer syndromes includ-
ing BRCA1, multiple endocrine neoplasia, familial adenomatous pol-
yposis, Li-Fraumeni syndrome, retinoblastoma and von Hippel-Lin-  http://dx.doi.org/10.5653/cerm.2011.38.3.126
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dau syndrome [24]. For hereditary breast and ovarian cancers caused 
by mutations in BRCA 1 and 2, the life-time risk of breast cancer for a 
female carrier may be as high as 85%, her risk of ovarian cancer as 
high as 60% [25].
PGH for unknown mutation sites of single gene 
disease
Preimplantation genetic haplotyping (PGH) can detect any mapped 
single gene diseases with unknown mutation sites [26]. It requires a 
comprehensive study of the pedigree with at least one affected fam-
ily member and finding multiple informative linked markers for the 
mutated genes before PGH can be performed. PGH has been suc-
cessfully applied to monogenic diseases following WGA with multi-
ple displacement amplification (MDA) [27,28]. PGH after WGA per-
mits examinations of a large number of polymorphic markers. 
PGD with HLA haplotyping and stem cell 
transplantation
In families having a diseased child with recessive genetic disorders 
such as Fanconi anemia or thalassemia, the couple undergoing PGD 
and HLA typing may not only avoid another genetically diseased 
child but also have a HLA-compatible sibling of the diseased child. 
The likelihood of a genetically normal and HLA-compatible embryo is 
3 in 16. Therefore, perhaps several treatment cycles would be needed 
before a pregnancy can be achieved. After birth of the neonate, um-
bilical cord blood can be collected and hematopoietic stem cell trans-
plantation can be applied to cure the diseased child [5,29]. The posi-
tive ethical background has been recently well discussed [30]. 
A potential, but uncertain, value of PGD for 
mitochondrial disease with unknown nuclear 
gene defects
PGD provides a reasonable option for mitochondrial disease with 
nuclear gene defects, like the treatment of autosomal recessive dis-
ease [2]. For the patients with unknown nuclear gene defects, the 
heredity of mitochondrial disease is uncertain. A woman carrying a 
mitochondrial DNA (mtDNA) mutation could be heteroplasmic and 
could transmit a various amount of mutation to her offspring. The 
phenotype can not be accurately predicted. In this situation, like pre-
natal diagnosis, the value of PGD would be doubtful because no defi-
nite disease-free diagnosis can be achieved. However, by transferring 
low mutant load of embryos, PGD may be performed to reduce the 
risk of disease for women with a high mutation load [31]. Technically, 
the high copy number of mtDNA makes the analysis feasible with 
less amplification failure and ADO [2]. But, the heteroplasmic charac-
teristics may raise a question concerning the representation of biop-
sied samples for the whole embryo. For embryo transfer, a cut-off 
point should be set regarding the mutant load of embryos. Preferen-
tial transfer of male embryos with low mutant load could be a moral-
ly acceptable way of avoiding transgenerational risks [32]. 
WGA permits individual detection of multiple 
gene loci and screening all 23 pairs of 
chromosomes
Single cell or few cells obtained for PGD contains very limited DNA 
material. In order to detect mutated gene and polymorphic markers, 
multiplex PCR was traditionally used. It is critical to design compatible 
multiple primer sequences and conditions when several PCR reactions 
may interfere mutually in a tube. If one of the PCR reactions failed, 
the detection procedures can not be repeated. The utilization of WGA 
to produce a DNA library could provide sufficient DNA templates for 
multiple independent examinations of gene mutations and polymor-
phic markers as well as repeating confirmations for an uncertain result. 
Different genotyping methods can also be used for double confirma-
tions of diagnosis [4]. The WGA products also allow detecting chro-
mosomal translocation and screening all 23 pairs of chromosomes.
A few WGA methods have been used in PGD [5,33]. Primer exten-
sion pre-amplification (PEP) using a random mixture of 15-base oli-
gonucleotides was estimated to amplify 91% genome of a cell. How-
ever, the microsatellite loci used for fingerprinting were not accurate-
ly amplified. OmniPlex converts randomly fragmented genomic DNA 
into a library, and has an amplification of >99.8% genome achieving 
a SNP call rate of >98%. MDA using bacteriophage Phi29 DNA poly-
merase and random hexamer primers is recently developed for WGA 
with unbiased amplification [13,34]. MDA is a non-PCR-based meth-
od that may prevent generation of relatively short DNA fragments and 
avoid possibility of mutation introduction [33]. A few clinical applica-
tions of MDA for PGD have been reported, such as for Marfan syn-
drome, Duchenne muscular dystrophy, cystic fibrosis, β-thalassemia, 
and Hungtington chorea, and neurofibromatosis type 1 [4]. The oth-
er WGA methods including linker adaptor and GenomePlex have 
been investigated [35,36]. The advantages of each WGA method in 
PGD deserve further studies.
PGD provides an alternative to achieve normal 
pregnancy for patients with chromosomal 
translocation
It is estimated that 1 in 625 individuals carries a balanced chromo-
somal translocation. In couples with recurrent miscarriage, the inci-www.eCERM.org
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dence of either of the couple being a carrier of a structural chromo-
some abnormality is approximately 4-5%, mainly including recipro-
cal translocations and Robertsonian translocations [37]. In the case of 
reciprocal translocation, at meiosis I during gametogenesis, the two 
pairs of homologous chromosomes associate at the pachytene stage 
to form a quadrivalent with matching of homologous segments. 
Several modes of segregation including 2:2 alternate, adjacent-1, ad-
jacent-2, 3:1 and 4:0 may occur. At meiosis II, anaphase non-disjunc-
tion may also happen. The theoretical chance of producing normal 
or balanced gametes is 4 of 32 for reciprocal translocation, and it is 4 
of 16 for Robertsonian translocations. However, the actual percent-
age depends on several factors, including which chromosomes in-
volved, the breakpoints, and the sex of the carrier [38]. The carriers of 
balanced chromosomal translocation are at increased risk for infertil-
ity, pregnancy loss, and offspring with congenital abnormalities and 
mental retardation as a result of unbalanced segregation. PGD pro-
vides an option to exclude the unbalanced embryos.
FISH is traditionally used for PGD of 
chromosomal translocation, but with technical 
difficulty
Initial research of chromosomal translocation using Fluorescence in-
situ hybridization (FISH) involved painting probes for metaphase 
chromosomes of polar bodies. A major shortcoming of this method is 
that only translocations of the female can be examined. Then, probes 
that spanned or flanked the translocation breakpoints were used for 
the interphase nucleus of a blastomere from cleavage-stage embry-
os. It can distinguish normal embryos from embryos of balanced and 
unbalanced translocation. But this methodology was restricted by 
the cost and the time needed to make specific probes. The subtelo-
mere probes in combination with centromeric probes are commonly 
used that obviated the need for specific probe development for each 
rearrangement [38,39]. But this strategy will not differentiate be-
tween normal and balanced embryos. The FISH method is technically 
difficult on fixation of blastomeres. Several drawbacks may be en-
countered including hybridization failure, signal overlap, and splitting 
that can affect the accuracy of the interpretation [40]. FISH analysis 
may offer a positive predictive value of 83% and negative predictive 
value of 81% [41]. Wrong results may eliminate normal/balanced em-
bryos for transfer, or lead to transfer of abnormal embryos. 
PCR-based PGD for chromosomal translocation 
avoids difficulty of cell fixation
The PCR-based PGD protocol for translocations has the potential to 
overcome several inherent limitations of FISH-based tests [17]. They 
are not dependent on cell fixation onto a microscope slide, a critical 
step that requires skill and experience, with the potential to increase 
the percentage of embryos with a positive result. It is easier to train 
staff in, and monitor, the placing of single cells into PCR tubes than 
teaching the fixation. It has potential improvements in terms of test 
performance, automation, turnaround time, sensitivity, and reliabili-
ty. Both FISH and PCR-based methods allow identification of aneu-
ploidies simultaneously, but only for a limited number of chromo-
somes. The array comparative genomic hybridization (CGH) after 
WGA has the above advantages and can detect all 24 chromosomes.
Array CGH detects translocation and 23 pairs of 
chromosomes and may replace FISH for PGD of 
chromosomal translocation
Array CGH permits visualization of all 46 interphase chromosomes. 
The tested sample genome is first amplified through WGA and la-
beled with one color. The normal reference sample is also amplified 
and labeled with another color. These samples are used as probes to 
hybridize onto normal metaphase chromosomal plates. With image-
processing software, unbalanced structural differences between the 
normal reference and test sample can be shown [42]. Array CGH pro-
vides the added benefit of simultaneous aneuploidy screening of all 
24 chromosomes [43,44]. Another advantage of array CGH is that it 
does not require preclinical validation before each IVF cycle, which is 
required for FISH. This avoids postponement of IVF treatment. Fioren-
tino et al. [44] reported 28 cycles of PGD at the cleavage embryo for 
chromosomal translocations. A high percentage of embryos (93%) 
were successfully diagnosed. Embryos suitable for transfer were in 
60% of started cycles. A 70% of pregnancy rate per transfer cycle was 
achieved. Array CGH merits further validation in the blastocyst biopsy.
SNP microarray can distinguish between normal 
chromosomes and balanced translocation
SNPs account for most gene variants found in humans and can be 
used as markers for genome-wide association study. SNP array analy-
sis after WGA not only explores chromosomal aberrations but also 
provides information of haplotypes [45]. It can distinguish between 
normal and balanced chromosomes in embryos from translocation 
carriers. In addition, SNP array can also screen aneuploidy of all 24 
chromosomes. Treff et al. [46] reported successful application of SNP 
array for PGD to distinguish between normal and balanced chromo-
somes in embryos from a translocation carrier. This may provide an 
important option for these patients to prevent their offspring from 
facing the same fertility problem.  http://dx.doi.org/10.5653/cerm.2011.38.3.126
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For patients of balanced chromosomal 
translocation, the live birth rates are similar 
between PGD and natural conception 
Franssen et al. [37] performed a systematic review and found that 
after natural conception, live birth rate per couple varied between 33 
and 60% (median 55%). After PGD, live birth rate per couple varied 
between 0 and 100% (median 31%). It has been reported that 15-
26% of the embryos were transferable in patients of reciprocal trans-
locations, confirming the high level of chromosomally abnormal em-
bryos [38]. This might explain why the results of PGD in some couples 
are relatively low [47]. Therefore, there are insufficient data indicating 
that PGD improves the live birth rate in couples with recurrent mis-
carriage carrying a structural chromosome abnormality.
PGD may shorten time to conceive and reduce 
miscarriage for patients of balanced 
chromosomal translocation
For patients with chromosomal translocation and repeated miscarri-
age, PGD may reduce time to get pregnancy. In the recent two reports, 
the cumulative pregnancy rate using PGD was 57-87%, involving an 
average of 1.2-1.4 cycles [48,49]. The short time (<4 months) under-
going PGD achieves pregnancy in contrast with the much longer inter-
val (mean, 4-6 years) for natural conception. Pregnancy loss rate was sig-
nificantly reduced to 13% post-PGD compared with 88. 5% in previous 
non-PGD pregnancies. This is close to a sevenfold reduction in loss rate. 
Costs and benefits of PGD in chromosomal 
translocation should be considered for each 
couple
PGD is an option when the couple with balanced translocation has 
also a fertility problem. For those couple without fertility difficulty, 
the costs and benefits should be considered in light of the limited 
change in live birth rate. PGD may shorten the time to achieve nor-
mal pregnancy and reduce miscarriage rate. The pregnancy rate is 
higher for selected patients with younger age and many good quali-
ty embryos available. But, the pregnancy rate would be lower for pa-
tient with older age and few embryos available. The possible treat-
ment options should be provided and discussed with the couple.
The rationales of PGS for advanced maternal 
age, idiopathic repeated pregnancy loss, recurrent 
aneuploidy, or repeated implantation failure 
Pregnancy rates and live birth rates decline with increasing mater-
nal age. Miscarriage rates increases also. The primary reason is high 
embryonic loss due to aneuploidy. It has been found that 50% of 
morphologically normal embryos in women >35 years old are chro-
mosomally abnormal [50]. More than 50% of first-trimester sponta-
neous abortions are chromosomal aneuploidy. Hence, it could be ef-
fective to increase live birth rates by performing PGS and transferring 
euploid embryos for patients of advanced maternal age, repeated 
implantation failure, and idiopathic recurrent pregnancy loss. It may 
be applied in single embryo transfer. It is supposed to improve im-
plantation rates, reduce miscarriages and trisomic offspring, and ulti-
mately lead to an increase in live birth rates [51,52]. However, aneu-
ploidy is not the absolute cause of implantation failure or idiopathic 
recurrent pregnancy loss. The cost and benefits of PGS should be 
considered for individual patients.
PGS using limited FISH probes in the cleavage-
stage embryos is not effective
Since the late 1990s, favorable ongoing pregnancy rates for advanc-
ed maternal age were achieved in initial studies using FISH-based 
PGS on cleavage-stage embryos [53]. However, the recent ten ran-
domized controlled trials have shown that PGS does not increase live 
birth rates, although these studies are all confounded by limited 
power. Meta-analysis of these trials shows a statistically significant 
reduction of ongoing pregnancies after PGS (13% after PGS, vs. 21% 
in the control group) [53]. For unexplained recurrent miscarriage, 
there were no randomized controlled trials on this topic. A systematic 
review was to assess live birth rates and miscarriage rates after PGS 
or natural conception [54]. From the limited data, a similar live birth 
rate is reported for PGS and natural conception (35% and 42%, re-
spectively). The miscarriage rate for the PGS group (9%) appears to 
be lower than in the natural conception group (28%). For repeated 
implantation failures, the existing data of PGS are also limited and in-
consistent. Some studies are suggestive of increased pregnancy rates 
for younger women (average age, 30-33 years), while others did not 
verify any advantage [55]. Overall, the present data are not sufficient 
to support the use of PGS and FISH at the cleavage-stage embryos to 
improve the live birth rates in patients with advanced maternal age, 
recurrent pregnancy loss, or repeated implantation failure. 
Polar body and blastocyst biopsy may 
circumvent the problem of mosaicism of the 
cleavage-stage embryo biopsy
Two major factors may explain the negative result of PGS and FISH 
on day 3 embryos, including chromosomal mosaicism and insuffi-
cient number of chromosomes tested [56]. The tested blastomere www.eCERM.org
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may not be representative for the whole embryo owing to mosaicism 
or the possibility of self-correction of aneuploidy within the embryo. 
As mosaicism is not present at the oocyte, it seems to be preferable 
to opt for polar body biopsy. The disadvantage of polar bodies is that 
only the maternal aneuploidies can be studied. However, the vast 
majority (more than 90%) of human aneuploidies is maternal origin. 
Testing the polar body is ethically acceptable in countries that do not 
allow testing of embryos. PGS at the blastocyst stages may provide 
more accurate information for chromosome abnormalities than at 
the cleavage stage. Although blastocysts may also display mosaicism, 
several cells can be biopsied at this stage that is more representative 
for the whole embryo [57]. 
PGS using blastocyst biopsy or polar body 
biopsy and array CGH may replace cleavage-
stage biopsy and limited FISH assay
Initial results for patients of advanced maternal age with repeated 
implantation failure receiving blastocyst biopsy and array CGH for 
PGS were encouraging [56]. Fragouli et al. [56] found that implanta-
tion and pregnancy rates for the patients with polar body biopsy were 
11% and 21%, respectively, whereas for patients receiving blastocyst 
biopsy they were 58% and 69%. Blastocyst analysis was associated 
with high pregnancy rates, suggesting that comprehensive chromo-
some screening may assist these patients in achieving pregnancies. 
Blastocyst or polar bodies biopsy using array CGH are recommended 
for randomized controlled trials for women of advanced maternal 
age, idiopathic recurrent abortions or repeated aneuploidy, and re-
peated implantation failure. 
Misdiagnosis may occur in PGD and prenatal 
confirmation is recommended
Some misdiagnoses of PGD had been reported in the literature [9, 
40]. The causes of misdiagnosis may include maternal or paternal 
contamination, ADO, and chromosomal mosaicism [40]. In face of 
the risk of misdiagnoses, prenatal diagnosis is recommended to con-
firm the PGD result when a pregnancy is achieved. 
PGD babies do not increase for congenital 
abnormalities
There are some cohort studies concerning the pediatric follow-up 
of PGD babies. Liebaers et al. [58] reported a thorough, systematic 
study of PGD offspring judged on the basis of a physical examination 
2 months after birth. Anomalies in PGD babies, compared to a previ-
ously reported cohort study of ICSI offspring, structural malforma-
tions were found in 2.13% for PGD and 3.38% for ICSI. Nekkebroeck 
et al. [59] found similar mental and psychomotor developmental 
outcomes at age 2 when compared with children conceived after ICSI 
and natural conception. PGD babies do not appear to be increased in 
anomalies.
Ethic aspect of PGD
PGD is gradually widely acceptable as an alternative to prevent the 
birth of a child with a hereditary disease including single gene disor-
der and chromosomal rearrangements. PGD for autosomal dominant 
late-onset disorders, cancer predisposition syndrome, PGD/HLA typ-
ing, and mtDNA mutations is more controversial. The experienced 
geneticist and infertility doctor should provide comprehensive coun-
seling to the couple and explain the theoretical percentage of unaf-
fected embryos. The severity of the disease, the age of onset of the 
disease, and the penetrance of the gene mutation are discussed. The 
odds of a misdiagnosis inherent to PCR or FISH are explained, and 
subsequent genotype confirmation of the pregnancy using conven-
tional prenatal diagnosis is indicated. The cost, risk, and benefits 
should be well-explained. The decision would be determined by the 
couples.
Conclusion
PGD gains a gradually important role in the prevention of Mende-
lian hereditary diseases and unbalanced chromosomal translocation. 
More indications have been applied as aneuploidy screening, HLA 
typing, adult-onset autosomal disease, cancer predisposition syn-
drome and mitochondrial disease. Polymorphic markers are essential 
to find ADO that prevents misdiagnosis. Blastocyst biopsy increases 
diagnostic accuracy that may replace the cleavage-stage biopsy. PGD 
may shorten time to conceive and reduce miscarriage for patients 
with chromosomal translocation. PGS using blastocyst biopsy and ar-
ray CGH is encouraging. Cryopreservation of biopsied blastocysts per-
mits sufficient time for molecular diagnosis. That may also circumvent 
risk of ovarian hyperstimulation syndrome and possible suboptimal 
endometrium. Array CGH can detect translocation and 23 pairs of 
chromosomes and may replace FISH for PGD of chromosomal trans-
location and PGS. PGD can currently offer with a high accuracy of 95-
99%, and may result in a pregnancy rate of 20-60%, depending on in-
dications and age.  
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